<DOC>
	<DOCNO>NCT00679900</DOCNO>
	<brief_summary>The primary objective compare potential next-day residual effect eplivanserin 5 mg/day lormetazepam 1 mg/day measure sleepiness morning use patient 's sleep questionnaire 4 week treatment patient chronic primary insomnia sleep maintenance difficulty . The secondary objective compare clinical safety product , include potential rebound insomnia withdrawal symptom treatment discontinuation , compare efficacy product subjective sleep parameter compare effect product patient 's daytime functioning .</brief_summary>
	<brief_title>Comparison Eplivanserin Lormetazepam Treatment Insomnia Characterized Sleep Maintenance Difficulties</brief_title>
	<detailed_description />
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Lormetazepam</mesh_term>
	<mesh_term>Lorazepam</mesh_term>
	<mesh_term>SR 46349B</mesh_term>
	<criteria>Primary Insomnia accord Diagnostic Statistical Manual Mental Disorders ( DSMIVTR ) criterion At least 1 hour wakefulness least 3 night per week month precede inclusion Disturbances sleep maintenance criterion base patient 's sleep questionnaire runin period Pregnant breastfeed woman woman childbearing potential without effective contraceptive method birth control Night shift worker individual nap 3 time per week Consumption xanthinecontaining beverage ( i.e. , tea , coffee cola ) comprise 5 cup glass per day Insomnia secondary general medical condition The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Primary Insomnia</keyword>
	<keyword>Sleep Maintenance Difficulties</keyword>
</DOC>